• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新辅助放化疗与新辅助化疗治疗食管鳞癌的生存和并发症：Meta 分析。

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis.

机构信息

Department of Radiation, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.

First Clinical College, Xuzhou Medical University, Xuzhou, China.

出版信息

PLoS One. 2022 Aug 5;17(8):e0271242. doi: 10.1371/journal.pone.0271242. eCollection 2022.

DOI:10.1371/journal.pone.0271242
PMID:35930539
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9355212/
Abstract

OBJECTIVES

To compare the survival and complications of neoadjuvant chemoradiation (NCRT) versus neoadjuvant chemotherapy (NCT) for esophageal squamous cell carcinoma (ESCC).

METHODS

We conducted a systematic literature search of the PubMed, Web of Science, Cochrane Library, EMBASE, CNKI, Wanfang Data, CBM, and VIP databases from inception to November 2021. Meta-analyses were performed using RevMan (version 5.3) and Stata version 15.0.

RESULTS

A total of 18 studies were included, which involved 3137 patients, The results of the metaanalysis showed that the pathological complete remission rate (odds ratio [OR] = 5.21, 95% confidence interval [CI]: 2.85-9.50, p<0.00001) and complete tumor resection rate (OR = 2.31, 95% CI: 1.57-3.41, p<0.0001) in the NCRT group were significantly better than those in the NCT group. Our meta-analysis results showed that 1-, 3-, and 5-year survival rates (1-year overall survival [OS]: OR = 1.51, 95% CI: 1.11-2.05, p = 0.009; 3-year OS: OR = 1.73, 95% CI: 1.36-2.21, p<0.0001; 5-year OS: OR = 1.61, 95% CI: 1.30-1.99, p<0.00001) in the NCRT group were significantly higher than those in the NCT group. NCRT can lead a significant survival benefit compared with NCT and there was no significant difference between the two neoadjuvant treatments in terms of postoperative complications.

CONCLUSION

The use of NCRT in the treatment of patients with ESCC patients showed significant advantages in terms of survival and safety relative to the use of NCT.

摘要

目的

比较新辅助放化疗（NCRT）与新辅助化疗（NCT）治疗食管鳞癌（ESCC）的生存和并发症情况。

方法

我们对 PubMed、Web of Science、Cochrane Library、EMBASE、CNKI、万方数据、CBM 和 VIP 数据库进行了系统的文献检索，检索时间从建库至 2021 年 11 月。使用 RevMan（版本 5.3）和 Stata 版本 15.0 进行荟萃分析。

结果

共纳入 18 项研究，涉及 3137 例患者。荟萃分析结果显示，NCRT 组的病理完全缓解率（比值比 [OR] = 5.21，95%置信区间 [CI]：2.85-9.50，p<0.00001）和完全肿瘤切除率（OR = 2.31，95% CI：1.57-3.41，p<0.0001）明显优于 NCT 组。本研究荟萃分析结果显示，NCRT 组的 1、3 和 5 年生存率（1 年总生存率 [OS]：OR = 1.51，95% CI：1.11-2.05，p = 0.009；3 年 OS：OR = 1.73，95% CI：1.36-2.21，p<0.0001；5 年 OS：OR = 1.61，95% CI：1.30-1.99，p<0.00001）明显高于 NCT 组。NCRT 治疗 ESCC 患者在生存方面较 NCT 有显著优势，且两种新辅助治疗方案在术后并发症方面无显著差异。

结论

与 NCT 相比，NCRT 用于 ESCC 患者治疗在生存和安全性方面具有显著优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/320e0060943b/pone.0271242.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/aaef2a2ac06d/pone.0271242.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/a558f3b735c1/pone.0271242.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/da82ef588561/pone.0271242.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/d78ba68a7b7d/pone.0271242.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/1b2d7b11aa91/pone.0271242.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/38bd882207ab/pone.0271242.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/320e0060943b/pone.0271242.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/aaef2a2ac06d/pone.0271242.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/a558f3b735c1/pone.0271242.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/da82ef588561/pone.0271242.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/d78ba68a7b7d/pone.0271242.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/1b2d7b11aa91/pone.0271242.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/38bd882207ab/pone.0271242.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cddc/9355212/320e0060943b/pone.0271242.g007.jpg

相似文献

1
Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis.新辅助放化疗与新辅助化疗治疗食管鳞癌的生存和并发症：Meta 分析。
PLoS One. 2022 Aug 5;17(8):e0271242. doi: 10.1371/journal.pone.0271242. eCollection 2022.
2
Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.新辅助放化疗与新辅助化疗治疗局部晚期食管癌的疗效和安全性：一项更新的荟萃分析。
Medicine (Baltimore). 2024 Jan 19;103(3):e36785. doi: 10.1097/MD.0000000000036785.
3
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.新辅助放化疗后与新辅助化疗后行微创食管切除术的局部晚期食管鳞癌患者的发病率和死亡率：一项随机临床试验。
JAMA Surg. 2021 May 1;156(5):444-451. doi: 10.1001/jamasurg.2021.0133.
4
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.新辅助化疗联合卡瑞利珠单抗对比单纯化疗和放化疗用于局部晚期食管鳞癌的围手术期结局。
Front Immunol. 2023 Feb 7;14:1066527. doi: 10.3389/fimmu.2023.1066527. eCollection 2023.
5
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.新辅助放化疗对比新辅助化疗后行微创食管切除术治疗局部进展期食管鳞癌：一项前瞻性多中心随机临床试验。
Ann Oncol. 2023 Feb;34(2):163-172. doi: 10.1016/j.annonc.2022.10.508. Epub 2022 Nov 15.
6
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.新辅助放化疗与新辅助化疗治疗食管鳞状细胞癌的比较：来自中国国家癌症中心的一项倾向评分匹配研究
J Cancer Res Clin Oncol. 2022 Apr;148(4):943-954. doi: 10.1007/s00432-021-03659-7. Epub 2021 May 19.
7
Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.新辅助化疗或放化疗联合免疫治疗局部可切除食管鳞癌的比较。
Front Immunol. 2024 May 8;15:1336798. doi: 10.3389/fimmu.2024.1336798. eCollection 2024.
8
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials.可切除食管鳞癌新辅助化疗或放化疗后的生存：随机临床试验的汇总分析。
Radiother Oncol. 2024 Nov;200:110517. doi: 10.1016/j.radonc.2024.110517. Epub 2024 Aug 30.
9
Concurrent radiotherapy cannot provide superiority of surgical oncological outcome and long-term survival rate in locally advanced esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy followed by minimally invasive esophagectomy.新辅助化疗联合微创手术治疗局部晚期食管鳞癌患者中，同期放化疗并不能提高手术肿瘤学结局和长期生存率。
Surg Endosc. 2023 Sep;37(9):7073-7082. doi: 10.1007/s00464-023-10203-w. Epub 2023 Jun 28.
10
The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.食管鳞癌的当前最佳多模态治疗方法：系统评价和荟萃分析。
Int J Surg. 2018 Dec;60:88-100. doi: 10.1016/j.ijsu.2018.10.037. Epub 2018 Oct 31.

引用本文的文献

1
Recurrence patterns and long-term survival of locally advanced esophageal cancer patients with pathological complete response after different neoadjuvant therapies followed by surgery.不同新辅助治疗后行手术治疗且达到病理完全缓解的局部晚期食管癌患者的复发模式及长期生存情况
BMC Cancer. 2025 Jul 1;25(1):1135. doi: 10.1186/s12885-025-14548-4.
2
Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning.食管癌的放射治疗计划：2024年美国放射肿瘤学会放射治疗计划指南
J Radiat Res. 2025 Jul 22;66(4):354-364. doi: 10.1093/jrr/rraf029.
3
Survival benefits of postoperative radiotherapy in esophageal cancer during the immunotherapy era:a retrospective cohort study based on the SEER database and a single-center registry in China.

本文引用的文献

1
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of locally advanced esophageal cancer: a population-based analysis.新辅助放化疗与新辅助化疗治疗局部晚期食管癌：基于人群的分析。
Int J Clin Oncol. 2022 Feb;27(2):340-347. doi: 10.1007/s10147-021-02056-x. Epub 2021 Nov 3.
2
Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis.单细胞转录组分析解析食管鳞状细胞癌生态系统。
Nat Commun. 2021 Sep 6;12(1):5291. doi: 10.1038/s41467-021-25539-x.
3
Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism.
免疫治疗时代食管癌术后放疗的生存获益：一项基于美国监测、流行病学和最终结果（SEER）数据库及中国单中心登记处的回顾性队列研究
Front Immunol. 2025 Feb 24;16:1548520. doi: 10.3389/fimmu.2025.1548520. eCollection 2025.
4
Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma.食管鳞状细胞癌新辅助放化疗或放疗后不同病理退缩类型的生存和复发模式的多机构分析
Cancer Med. 2025 Feb;14(4):e70676. doi: 10.1002/cam4.70676.
5
Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study.新辅助化疗联合免疫治疗后达到完全病理缓解的食管癌患者3年无复发生存率更高：一项两中心倾向评分匹配研究
Front Oncol. 2025 Jan 14;14:1463936. doi: 10.3389/fonc.2024.1463936. eCollection 2024.
6
Neoadjuvant Chemotherapy vs Chemoradiotherapy for Malignancy of Esophagus: A Prospective Comparative Study.新辅助化疗与放化疗治疗食管癌的前瞻性对比研究
Cureus. 2024 Nov 12;16(11):e73525. doi: 10.7759/cureus.73525. eCollection 2024 Nov.
7
Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.新辅助放化疗与新辅助化疗治疗局部晚期食管癌的疗效和安全性：一项更新的荟萃分析。
Medicine (Baltimore). 2024 Jan 19;103(3):e36785. doi: 10.1097/MD.0000000000036785.
8
Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know.需要手术干预的接受全身抗癌治疗的患者：外科医生需要了解的内容。
Cancers (Basel). 2023 Jul 26;15(15):3781. doi: 10.3390/cancers15153781.
基于术前炎症状态和肿瘤葡萄糖代谢对食管癌新辅助放化疗反应的良好预测。
Sci Rep. 2021 Jun 2;11(1):11626. doi: 10.1038/s41598-021-90753-y.
4
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.新辅助放化疗与新辅助化疗治疗食管鳞状细胞癌的比较：来自中国国家癌症中心的一项倾向评分匹配研究
J Cancer Res Clin Oncol. 2022 Apr;148(4):943-954. doi: 10.1007/s00432-021-03659-7. Epub 2021 May 19.
5
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.纳武利尤单抗辅助治疗食管或胃食管结合部癌。
N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.
6
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.新辅助化疗与新辅助放化疗治疗食管癌的疗效和生存：逆倾向评分加权分析。
Eur J Surg Oncol. 2020 Dec;46(12):2248-2256. doi: 10.1016/j.ejso.2020.06.038. Epub 2020 Jul 10.
7
Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline.局部晚期食管癌的治疗：ASCO 指南。
J Clin Oncol. 2020 Aug 10;38(23):2677-2694. doi: 10.1200/JCO.20.00866. Epub 2020 Jun 22.
8
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).新辅助化疗与新辅助放化疗治疗局部晚期食管鳞癌：一项单中心、开放标签、随机、对照、临床研究（HCHTOG1903）。
BMC Cancer. 2020 Apr 15;20(1):303. doi: 10.1186/s12885-020-06824-2.
9
Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.多西他赛、顺铂和氟尿嘧啶治疗食管癌患者中培格非格司亭的早期给药：一项 II 期研究。
Cancer Sci. 2019 Dec;110(12):3754-3760. doi: 10.1111/cas.14218.
10
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.食管和胃食管交界处癌，2019 年第 2 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883. doi: 10.6004/jnccn.2019.0033.